316810-82-9

Basic information

• Product Name: 5-BROMO-7-NITRO-1H-INDAZOLE
• Synonyms: 5-BROMO-7-NITRO-1H-INDAZOLE
• CAS NO: 316810-82-9
• Molecular Formula: C₇H₄BrN₃O₂
• Molecular Weight: 242.03
• Product Categories: Indazoles
• Mol File: 316810-82-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 220°C
• Boiling Point: 420.8±25.0 °C(Predicted)
• Appearance: /
• Density: 1.965±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.77±0.40(Predicted)
• CAS DataBase Reference: 5-BROMO-7-NITRO-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-7-NITRO-1H-INDAZOLE(316810-82-9)
• EPA Substance Registry System: 5-BROMO-7-NITRO-1H-INDAZOLE(316810-82-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 316810-82-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-7-Nitro-1H-Indazole is a synthetic compound used mainly as a constituent in a range of chemical reactions due to its inhibitory properties. Its molecular formula is C7H4BrN3O2 and its molar mass is 260.035 g/mol. It is also known to be involved in the production of pharmaceuticals and other organic compounds. The presence of the bromo and nitro groups plays a key role in its reactivity and binding ability with other compounds. As such, it is often used in fluorogenic probe preparation, bioconjugation applications, and chemical biology research. Like other chemicals, it should be handled with care due to its potential hazards. Its purity and quality are typically monitored using certain analytical techniques like NMR spectroscopy.

Upstream product

• 77811-44-0 4-bromo-2-methyl-6-nitroaniline 
• 570-24-1 2-Methyl-6-nitroaniline 

Downstream Products

• 316810-86-3 5-bromo-1H-indazol-7-amine 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Indazole compounds containing nitrogen substituents, and application of same as IDO inhibitors

The invention discloses nitrogen substituent-containing indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application ofthe compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections relatedto cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Discovery of a novel series of N-phenylindoline-5-sulfonamide derivatives as potent, selective, and orally bioavailable Acyl CoA:monoacylglycerol acyltransferase-2 inhibitors

Acyl CoA:monoacylglycerol acyltransferase-2 (MGAT2) has attracted interest as a novel target for the treatment of obesity and metabolic diseases. Starting from N-phenylbenzenesulfonamide derivative 1 with moderate potency for MGAT2 inhibition, we explored